To confirm that the genes of the Japanese are more homozygous in terms of MHC than those of people in other countries, we evaluated the data concerning HLA antigens from the 11th HLA Conference and those from our own study. This study consisted of 4,166 Japanese and 7,717 non-Japanese who were examined for HLA antigens. The incidence of heterozygotes at all HLA class I and II loci in Japanese and in non-Japanese was 103% and 24.0%, respectively, whereas that of homozygotes was 40.5% and 27.5%, respectively. Our results led to the conclusion that Japanese individuals are more homozygous than foreigners, resulting in different incidences of both benign and malignant diseases, different responses to both medical and surgical therapy, and different immune responses to viral and bacterial infection.
Introduction
Human leukocyte antigens (HLA), glycoproteins present on the surface membranes of nearly every cell in the body, are located on chromosome number six. They are found in high concentrations on the surfaces of white blood cells (i. e., leukocytes) and are the major histocompatibility antigens for tissue recognition. HLA antigens are very polymorphic. Their main function is to help the immune system defend against invaders such as bacteria, viruses, parasites, and also cancers. The phenomenon of MHC restriction was first recognized by Doherty and Zinkernagel, who hypothesized that the great diversity of HLA class I and class II genes is maintained throughout infectious diseases (Doherty and Zinkernagel, 1975a;  Correspondence to: Kyoji Ogoshi, MD, Ph. D. Professor, Department of Surgery, Tokai University, Bohseidai, Isehara, Kanagawa, 259-1193 Japan ANNALS OF Cancer Research and Therapy Doherty and Zinkernagel, 1975b; Zinkernagel, 1996) . This phenomenon of overdominant selection (heterozygote advantage) in human infectious diseases has been reported only in patients with human immunodeficiency virus-type 1 infection and in those with hepatitis B virus infection (Thursz, Thomas, et al., 1997; Thio, Carrington, et al., 1999) . That is to say, all heterozygotes are favored over all homozygotes, as proposed by Flaherty (Flaherty, 1988) .
We previously reported that cancer patients with heterozygous or homozygous alleles at HLA class I and II loci have comparatively greater resistance to and more susceptibility to cancer, respectively, though this was not found to affect outcome (Ogoshi, unpublished observations), and that the extent of gastric resection and preservation of the duodenal passage affects the immune condition of patients and their outcome following gastrectomy, depending on the MHC polymorphism (Ogoshi, unpublished observations).
Since Japan is geographically isolated and there has been virtually no inward migration. we speculate that Japanese genes are more homozygous in terms of MHC than those of people from other countries. The aim of this study is confirm this speculation using the data of the 11th HLA Conference and our own data.
Materials and Methods
This study consisted of 4,166 Japanese and 7,717 non-Japanese who were examined for HLA antigens. Among the 4,166 Japanese people, 2,777 were patients with histologically confirmed cancer, 319 patients with a benign disease (peptic ulcer, gall bladder stone, common bile duct stone, colon polyp, colitis, etc), and 1,070 normal subjects. The data of non-Japanese and those of 945 normal Japanese subjects were obtained from the data of the 11th HLA conference, and the data of 125 subjects were obtained from Tokai University.
HLA typing
HLA antigens examined at Tokai University were serologically tested using the NIH onto Lymphoprep (Nycomed, Oslo, Norway), followed by centrifugation. For class I typing, cryopreserved peripheral blood lymphocytes were subjected to a complement-dependent microcytotoxicity assay using antisera to HLA-A, -B, and -C locus antigens. Class II typing was carried out on cells enriched for class II-positive lymphocytes using magnetic beads coated with a class II monoclonal antibody (Dynal, Oslo, Norway). These cells were subjected to a complement-dependent microcytotoxicity assay using antisera to HLA-DR and DQ antigens. Lymphocytes were typed for the following 49 antigens: A loci-1, 2, 3, 11, 24, 26, 31, 33; 13, 17, 27, 35, 37, 39, 44, 46, 48, 51, 52, 54, 55, 56, 59, 60, 61, 62, 67; w3, w4, w6, w7; 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13 ; DQ loci-1, 2, 3, 4.
Heterozygous/homozygous patients
Patients with homozygotes at HLA-A, -B, -C, -DR, or -DQ loci were defined as having only one detectable antigen at each locus. The patients with heterozygotes at class 1 and those with heterozygotes at class 2 were defined as having all detectable and different forms of antigens at HLA-A, -B, and -C loci and at -DR and -DQ loci, respectively. Therefore, patients with heterozygotes at class 1 and 2 were defined as having 10 different antigens, and those with heterozygotes at class 1 and homozygotes at class 2 were defined as having 6 different antigens at HLA-A, -B, and -C and one or more homozygous antigens at the HLA-DR or -DQ locus. Patients with homozygotes at class 1 and heterozygotes at class 2 were defined as having one or more homozygous antigens at the HLA-A, -B, or -C locus and as having 2 different antigens at the HLA-DR and -DQ loci. Patients with homozygotes at class 1 and 2 were defined as having one or more homozygous antigens at class 1 and 2.
Statistical analysis
We used the chi-square test to compare the prevalence of characteristics. Results were considered significant when the p value (two-tailed) was less than 0.05. Relative risk (RR) and 95% confidence intervals (CI) were calculated with a significant level of 0.05.
All statistical analyses were carried out using SPSS 10.0 software (SPSS Inc., Chicago, Illinois, USA). 
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Results
The incidence of heterozygotes and homozygotes at HLAs in Japanese and in nonJapanese and the incidence according to the sites of cancer are shown in Tables I and II. The incidence of heterozygotes at HLAs in Japanese and in non-Japanese with 5 different antigens at HLA-A, -B, -C, -DR, and DQ locus, was 24.0% and 10.3%, respectively ( Table I ). The relative risks of cancer in non-Japanese were higher than those in Japanese (Table III) , whereas the relative risks of benign disease were different between Japanese and non-Japanese (Table IV) . Non-Japanese individuals with homozygous alleles at HLA-DR had greater susceptibility to cancer compared to Japanese individuals (Table V) , and those with homozygous alleles at both HLA-DR and -DQ loci had greater susceptibility to cancer compared to non-Japanese individuals (Table VI) .
Discussion
The identification of a genetic polymorphism, such as a single-nucleotide polymorphism (SNP), is important in determining an individual's risk of cancer, response to therapy, or the possible toxicity of a particular treatment. The major histocompatibility complex (MHC) may be one of the better model systems for a multi-gene complex with welldefined genes and species variation. Yet because of its complexity, many geneticists and clinicians have hesitated to perform an in-depth study of the polymorphism and diversity of the MHC. There is evidence that MHC polymorphism is maintained by positive selection, most likely by overdominant selection (Hughes and Nei, 1988) , which may be related to the role MHC plays in presenting foreign peptides to T cells. The mammalian MHC has processes that lead to immune defenses. The main function of the MHC molecules is peptide-binding and presentation of peptides to T lymphocytes (Parham and Ohta, 1996; Townsend and Bodmer, 1989) . The inflammatory process is also known to play a significant role in the pathogenesis of cancers due to persistent infections, including the hepatitis B and C viruses (Imperial, 1999) , the human papilloma viruses (Cuzick, Sasieni et al., 2000) and Helicobacter pylori (Blaser, 1998) . The authors of the present study note that our findings lend strong support to the hypothesis of overdominant selection ("heterozygote advantage") at MHC due to selective pressure from cancers. It has been suggested that the hypothetical advantage of heterozygosity at HLA, with respect to increased resistance to cancer, may be responsible, at Our results also lead to the conclusion that Japanese individuals are more homozygous than individuals from other countries, resulting in different incidences of both benign and malignant diseases, different responses to both medical and surgical therapy, and different immune responses to viral and bacterial infection. For that reason, both prevention and therapy for cancer in Japanese subjects should be different from those subjects in other countries.
Thus, it is very useful for individuals from other countries to be aware of this difference in medical practices. Plans to examine the genotypes of these samples used in the present study and the therapies administered to patients are currently underway in our department.
